BRAF Kinase

Many tumors exhibit a high frequency of mutation in the BRAF kinase. Melanoma is the most significant with a 60-70% mutation rate, followed by colon with a 20% mutation rate and glioblastoma with a 12% mutation rate.

Using its unique approach to kinase drug discovery, Ambit has identified multiple series of BRAF inhibitors with sub-micromolar potency. Ambit has identified a potent and selective BRAF inhibitor as part of a broad collaboration with Cephalon.